James M. Mock is CFO at Moderna, Inc. (MRNA). They have made 13 open-market trades across 2 companies since 2020, most recently 2026-10-05.
CIK 0001736359
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MRNA | SELL · 10b5-1 | 2026-09-10 | 2026-09-14 | $134.49 | $4.7M | +32.6% | +53.5% | — |
| MRNA | SELL | 2024-11-29 | 2024-12-02 | $42.79 | $122K | -2.6% | -4.5% | -31.2% |
| MRNA | SELL | 2024-10-07 | 2024-10-08 | $60.12 | $43K | -7.3% | -13.8% | -27.0% |
| MRNA | SELL | 2024-08-29 | 2024-08-30 | $78.03 | $13K | -10.1% | -13.8% | -44.5% |
| MRNA | SELL | 2024-08-28 | 2024-08-29 | $79.39 | $210K | +1.3% | -14.8% | -44.7% |
| MRNA | SELL | 2024-07-08 | 2024-07-09 | $118.24 | $163K | +4.3% | -27.4% | -49.4% |
| MRNA | SELL | 2024-06-03 | 2024-06-04 | $140.72 | $194K | -4.6% | -19.4% | -50.3% |
| MRNA | SELL | 2024-05-29 | 2024-05-30 | $144.50 | $26K | -2.4% | -23.8% | -48.5% |
| MRNA | SELL | 2024-05-28 | 2024-05-29 | $162.47 | $211K | -1.2% | -21.0% | -47.5% |
| MRNA | SELL | 2024-04-08 | 2024-04-09 | $101.93 | $144K | -5.8% | +14.0% | +8.2% |
| MRNA | SELL | 2024-02-29 | 2024-03-01 | $94.57 | $122K | +12.5% | +11.6% | +60.1% |
| MRNA | SELL · 10b5-1 | 2024-01-08 | 2024-01-09 | $109.75 | $85K | -9.4% | -14.9% | -4.5% |
| MRNA | SELL · 10b5-1 | 2023-10-06 | 2023-10-10 | $102.50 | $293K | -23.4% | -33.8% | +10.0% |
| PKI | SELL | 2022-06-24 | 2022-06-27 | $145.49 | $1.5M | +1.0% | +4.3% | -16.6% |
| PKI | SELL | 2021-09-20 | 2021-09-21 | $184.75 | $1.7M | -6.4% | -4.8% | +1.5% |
| PKI | SELL | 2020-10-02 | 2020-10-05 | $124.49 | $1.3M | -4.8% | +4.2% | +12.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.